Vigabatrin (Sabril)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Developmental and Epileptic Encephalopathies, Focal Onset Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Featured evidence outside this drug's tracked markets:ViRap (NCT04987463) · Tuberous Sclerosis Complex · Phase 2/3 · Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 2/3 (2)
Other / comorbidity
NCT04987463 · Katarzyna Kotulska
2021-05-07 – 2028-12 · Tuberous Sclerosis Complex
What this study did
NCT01281202 · Catalyst Pharmaceuticals, Inc.
2011-01 – 2012-12 · Cocaine Addiction, Cocaine Dependence
What this study did
Phase 2 (9)
Epilepsy
NCT04772547 · University of Florida
2021-09-22 – 2024-01-23 · Status Epilepticus, Electrographic, Coma
What this study did
Other / comorbidity
NCT04062890 · University of Arizona
2030-04-15 – 2030-12-30 · Hyperinsulinism, Insulin Resistance, Insulin Sensitivity, Glucose Intolerance, Hypertension
What this study did
NCT04321395 · Washington University School of Medicine
2021-08-23 – 2024-05-15 · NAFLD, Obesity
What this study did
NCT01335867 · University of Pennsylvania
2011-04 – 2013-12 · Alcoholism, Cocaine Dependence
What this study did
NCT00611130 · Catalyst Pharmaceuticals, Inc.
2008-01 – 2012-10 · Cocaine Dependence
What this study did
NCT00730522 · Catalyst Pharmaceuticals, Inc.
2008-07 – 2009-11 · Methamphetamine Dependence
What this study did
NCT00527683 · NYU Langone Health
2007-04 – 2007-11 · Cocaine Dependence
What this study did
NCT00373581 · New York State Psychiatric Institute
2006-04 – 2006-12 · Cocaine Dependence
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01585207 · Barbara J. Coffey
2012-07 – 2015-03 · Tourette's Disorder
What this study did
Phase 1 (2)
Other / comorbidity
NCT04468282 · Orphelia Pharma
2017-04-04 – 2017-08-08 · Therapeutic Equivalency
What this study did
NCT00626834 · National Institute on Drug Abuse (NIDA)
2008-02 – 2010-10 · Cocaine Addiction
What this study did
Phase 4 (3)
Epilepsy
NCT01413711 · Lundbeck LLC
2012-06 – 2013-09 · Infantile Spasms
What this study did
Focal Onset Seizures
NCT01278173 · Lundbeck LLC
2010-12 – 2015-05 · Adult Refractory Complex Partial Seizures
What this study did
NCT01266291 · University of Pennsylvania
2010-08 – 2013-12 · Complex Partial Seizures
What this study did
Early phase / not applicable (3)
Epilepsy
NCT04302116 · Kullasate Sakpichaisakul
2020-05-18 – 2026-12 · Infantile Spasm, West Syndrome
What this study did
NCT02220114 · Orphelia Pharma
2014-05 – 2016-12 · Infantile Spasms
What this study did
Other / comorbidity
NCT03003143 · Seoul National University Hospital
2016-11 – 2020-09-09 · Autoimmune Encephalopathy
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Epilepsy
NCT05128344 · Amzell
2023-04 – 2025-12 · Spasms, Infantile
What this study did
NCT03347526 · University of Colorado, Denver
2018-04-19 – 2021-08 · Infantile Spasm
What this study did
NCT02299115 · The Hospital for Sick Children
2017-09-05 – 2019-03-06 · Infantile Spasms
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Epilepsy
NCT03421496 · Radius Pharmaceuticals, Inc.
2018-09-05 – 2019-05-29 · Infantile Spasm
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vigabatrin (Sabril): this drugApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001).
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022).
RufinamideApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vigabatrin (Sabril) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 2/3Tuberous Sclerosis ComplexRecruiting
Est. primary completion 2028-12 · NCT04987463 · CT.gov ↗
What to watch

See the full readout calendar ↗